



US 20210254166A1

(19) **United States**(12) **Patent Application Publication**
WALKER et al.(10) **Pub. No.: US 2021/0254166 A1**(43) **Pub. Date: Aug. 19, 2021**(54) **GENE SIGNATURES PREDICTIVE OF METASTATIC DISEASE**(30) **Foreign Application Priority Data**

Jun. 17, 2015 (GB) 1510684.2

(71) Applicant: **ALMAC DIAGNOSTICS LIMITED,**
Craigavon (GB)**Publication Classification**(72) Inventors: **Steven WALKER**, Craigavon (GB);
Laura HILL, Craigavon (GB);
Andrena MCCAVIGAN, Derryadd
(GB); **Sinead DONEGAN**, Belfast
(GB); **Timothy DAVISON**,
Hillsborough (GB); **Richard**
KENNEDY, Belfast (GB); **Denis Paul**
HARKIN, Dromore (GB); **Bethanie**
PRICE, Craigavon (GB)(51) **Int. Cl.**
C12Q 1/6886 (2006.01)(52) **U.S. Cl.**
CPC **C12Q 1/6886** (2013.01); **C12Q 2600/158**
(2013.01); **C12Q 2600/118** (2013.01)(73) Assignee: **ALMAC DIAGNOSTICS LIMITED,**
Craigavon (GB)(57) **ABSTRACT**

Methods for characterising and/or prognosing cancer in a subject comprise determining the expression level of at least one, and preferably 12, genes selected from Table 1 in a sample from the subject wherein the determined expression level is used to provide a characterisation of and/or a prognosis for the cancer. Determined expression levels are used to generate a signature score. The methods permit metastatic disease to be identified and monitored and guide therapeutic interventions.

Specification includes a Sequence Listing.(21) Appl. No.: **15/736,667**(22) PCT Filed: **Jun. 17, 2016**(86) PCT No.: **PCT/GB2016/051825**

§ 371 (c)(1),

(2) Date: **Dec. 14, 2017**